Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Werewolf Therapeutics Inc shares valued at $275,985 were purchased by RA CAPITAL MANAGEMENT, L.P. on May 12 ’25. At $0.86 per share, RA CAPITAL MANAGEMENT, L.P. acquired 320,913 shares. The insider’s holdings grew to 6,021,969 shares worth approximately $7.41 million following the completion of this transaction.
Also, RA CAPITAL MANAGEMENT, L.P. purchased 162,539 shares, netting a total of over 159,288 in proceeds. Following the buying of shares at $0.98 each, the insider now holds 6,237,482 shares.
Before that, RA CAPITAL MANAGEMENT, L.P. had added 52,974 shares to its account. In a trade valued at $51,915, the Director bought Werewolf Therapeutics Inc shares for $0.98 each. Upon closing the transaction, the insider’s holdings increased to 52,974 shares, worth approximately $7.47 million.
As published in their initiating research note from JMP Securities on April 03, 2024, Werewolf Therapeutics Inc [HOWL] has been a Mkt outperform and the price target has been revised to $12. Analysts at Wedbush started covering the stock with ‘”an Outperform”‘ outlook in a report released in late August. Earlier on September 10, 2021, BofA Securities initiated its rating. Their recommendation was “a Buy” for HOWL stock.
Analyzing HOWL Stock Performance
During the last five days, there has been a drop of approximately -3.91%. Over the course of the year, Werewolf Therapeutics Inc shares have dropped approximately -16.89%. Shares of the company reached a 52-week high of $1.7200 on 01/03/25 and a 52-week low of $0.5950 on 04/07/25.
Support And Resistance Levels for Werewolf Therapeutics Inc (HOWL)
According to the 24-hour chart, there is a support level at 1.1472, which, if violated, would cause prices to drop to 1.0645. In the upper region, resistance lies at 1.3455. The next price resistance is at 1.4611. RSI (Relative Strength Index) is 58.27 on the 14-day chart, showing neutral technical sentiment.
